Camrelizumab plus famitinib significantly improved PFS and OS compared to platinum-based chemotherapy in recurrent/metastatic cervical cancer. The trial reported a median PFS of 11.1 months for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback